Journal Detail Information

1

Cite

Share

Guidelines for vaccination of dogs and cats in Korea.

Woo Jin SONG ; Hyun Tae KIM ; Han Sang YOO ; Hwa Young YOUN

Clinical and Experimental Vaccine Research.2014;3(2):244-247. doi:10.7774/cevr.2014.3.2.244

This guideline contains the recommended vaccination schedules of dogs and cats from World Small Animal Veterinary Association (WSAVA) and American Animal Hospital Association (AAHA). In 2010, WSAVA published guidelines for the vaccination of dogs and cats. And, in 2011, AAHA also published guidelines for vaccination of dogs. In Korea, there is no published guideline for vaccination of dogs and cats yet. Therefore, the plane of vaccination also reports the present situation of vaccination schedule of dogs and cats in Korean animal hospitals.
Animals ; Appointments and Schedules ; Cats* ; Dogs* ; Hospitals, Animal ; Korea ; Vaccination*

2

Cite

Share

DNA immunization of Mycobacterium tuberculosis resuscitation-promoting factor B elicits polyfunctional CD8+ T cell responses.

Jino LEE ; Jihye KIM ; Jeewon LEE ; Sung Jae SHIN ; Eui Cheol SHIN

Clinical and Experimental Vaccine Research.2014;3(2):235-243. doi:10.7774/cevr.2014.3.2.235

PURPOSE: T cell-mediated immune responses, and particularly activation of polyfunctional T cells that simultaneously produce multiple cytokines, are necessary for the control of Mycobacterium tuberculosis. In the present study, we examined if DNA immunization of Mycobacterium tuberculosis resuscitation-promoting factor B (RpfB) elicits polyfunctional T cell responses in mice. MATERIALS AND METHODS: C57BL/6 mice were immunized intramuscularly three times, at 3-week intervals, with RpfB-expressing plasmid DNA. For comparison, protein immunization was performed with recombinant RpfB in control mice. After immunization, RpfB-specific T cell responses were assessed by interferon-gamma (IFN-gamma) enzyme-linked immunosorbent spot assay and intracellular cytokine staining (ICS), and T cell polyfunctionality was assessed from the ICS data. RESULTS: RpfB DNA immunization induced not only humoral immune responses, but also CD8+ and CD4+ T cell responses. Immunodominant T-cell epitopes were identified within RpfB by assays with overlapping peptides. RpfB DNA immunization elicited a polyfunctional CD8+ T cell response that was dominated by a functional phenotype of IFN-gamma+/TNF-alpha+/IL-2-/CD107a+. CONCLUSION: RpfB DNA immunization elicits polyfunctional CD8+ T cell responses, suggesting that RpfB DNA immunization might induce protective immunity against tuberculosis.
Animals ; Complement Factor B* ; Cytokines ; DNA* ; Epitopes, T-Lymphocyte ; Immunity, Humoral ; Immunization* ; Interferon-gamma ; Mice ; Mycobacterium tuberculosis* ; Peptides ; Phenotype ; Plasmids ; T-Lymphocytes ; Tuberculosis ; Vaccines, DNA

3

Cite

Share

Lumazine synthase protein cage nanoparticles as antigen delivery nanoplatforms for dendritic cell-based vaccine development.

Jae Sun RA ; Hyun Hee SHIN ; Sebyung KANG ; Yoonkyung DO

Clinical and Experimental Vaccine Research.2014;3(2):227-234. doi:10.7774/cevr.2014.3.2.227

PURPOSE: Protein cages are promising nanoplatform candidates for efficient delivery systems due to their homogenous size and structure with high biocompatibility and biodegradability. In this study, we investigate the potential of lumazine synthase protein cage as an antigen delivery system to dendritic cells (DCs), which induce antigen-specific T cell proliferation. MATERIALS AND METHODS: Ovalbumin (OVA) peptides OT-1 (SIINFEKL) and OT-2 (ISQAVHAAHAEINEAGR) were genetically inserted to lumazine synthase and each protein cage was over-expressed in Escherichia coli as a soluble protein. The efficiency of antigen delivery and the resulting antigen-specific T cell proliferation by DCs was examined in vitro as well as in vivo. RESULTS: We successfully generated and characterized OVA peptides carrying lumazine synthase protein cages. The OT-1 and OT-2 peptides carried by lumazine synthases were efficiently delivered and processed by DCs in vitro as well as in vivo, and induced proliferation of OT-1-specific CD8+T cells and OT-2-specific CD4+T cells. CONCLUSION: Our data demonstrate the potential of lumazine synthase protein cage being used as a novel antigen delivery system for DC-based vaccine development in future clinical applications.
Antigen Presentation ; Cell Proliferation ; Dendritic Cells ; Escherichia coli ; Nanoparticles* ; Ovalbumin ; Ovum ; Peptides ; Vaccines

4

Cite

Share

First trials of oral vaccination with rabies SAG2 dog baits in Morocco.

Sami DARKAOUI ; Franck BOUE ; Jean Michel DEMERSON ; Ouafaa FASSI FIHRI ; Khadija Id Sidi YAHIA ; Florence CLIQUET

Clinical and Experimental Vaccine Research.2014;3(2):220-226. doi:10.7774/cevr.2014.3.2.220

PURPOSE: Canine rabies is a serious health problem in Morocco and about 22 human deaths are reported yearly. Following the World Health Organization (WHO) recommendations, Moroccan authorities evaluated oral rabies vaccine baits specially designed for dogs. MATERIALS AND METHODS: The study was performed in Tiflet area. The vaccine strain was SAG2, a modified live oral rabies vaccine strain. Each bait contained an aluminium/PVC capsule filled with a liquid. Two kinds of baits were used: placebo baits containing methylene blue as a topical marker and vaccine baits containing vaccine suspension. The study was performed according to recommended WHO strategies, i.e., door to door model (DDDM), hand-out and wildlife immunization model (WIM). The DDDM was performed in the rural area of Tiflet on 60 owned dogs. The hand-out strategy was tested on 15 stray dogs. The WIM was performed on 4 transects lines near Tiflet slaughterhouse and near the weekly traditional market location. RESULTS: Using the DDDM, 100% of owned dogs were attracted by the baits and 77% ate the bait. Using the hand-out model, 100% of dogs showed interest in baits and 46.7% took the baits. Using the WIM in stray dogs, up to 73% of baits disappeared and 68% of the capsules containing the SAG2 vaccine were found pierced, depending on the sites of distribution. CONCLUSION: This pilot study showed that baits have a good palatability and that oral vaccination of both owned and stray dogs is feasible with baits specifically developed for dogs and with adapted strategy of distribution.
Abattoirs ; Administration, Oral ; Animals ; Capsules ; Dogs* ; Humans ; Immunization ; Methylene Blue ; Morocco* ; Pilot Projects ; Rabies Vaccines ; Rabies* ; Vaccination* ; World Health Organization

5

Cite

Share

Inactivated genotype 1 Japanese encephalitis vaccine for swine.

Dong Kun YANG ; Jin Ju NAH ; Ha Hyun KIM ; Jae Young SONG

Clinical and Experimental Vaccine Research.2014;3(2):212-219. doi:10.7774/cevr.2014.3.2.212

PURPOSE: Japanese encephalitis is a reproductive disorder caused by Japanese encephalitis virus (JEV) in swine. Recent genotype (G) shift phenomenon (G3 to G1) in the Asia-wide has posed a challenge for proper prevention by the current vaccine strain. Thus, new kinds of JEV G1 vaccines with enhanced immunogenicity have been required for pigs. MATERIALS AND METHODS: Recombinant porcine granulocyte monocyte-colony stimulating factor (reporGM-CSF) protein was expressed in Spodoptera frugiperda (Sf-9) cells using baculovirus expression system. Two kinds of trials with inactivated JEV vaccines containing IMS1313 adjuvant (Seppic, France) were prepared with or without reporGM-CSF protein. Safety and immunogenicity of the pigs inoculated with the JEV vaccines via intramuscular route was evaluated for 28 days after inoculation. RESULTS: Mice, guinea pigs, and fattening pigs inoculated with the inactivated vaccine showed no signs for 14 and 21 days. Both hemagglutination inhibition and plaque reduction neutralizing antibody titers were significantly higher in pigs immunized with the vaccine containing reporGM-CSF protein after boosting. However, on the side of vaccine efficacy, most mice (87%) immunized with the inactivated JEV vaccine survived after virulent JEV challenge. Whereas the group with the vaccine containing reporGM-CSF protein showed lower protective effects than the vaccine alone for the biological activity of the GM-CSF depending on species specific. CONCLUSION: Our data indicate that animals inoculated with the JEV vaccines was safe and pigs inoculated with inactivated JEV vaccine containing reporGM-CSF protein showed higher humoral immune responses than that of inactivated JEV vaccine without reporGM-CSF protein.
Animals ; Antibodies, Neutralizing ; Baculoviridae ; Encephalitis Virus, Japanese ; Encephalitis, Japanese* ; Genotype* ; Granulocyte-Macrophage Colony-Stimulating Factor ; Granulocytes ; Guinea Pigs ; Hemagglutination ; Immunity, Humoral ; Mice ; Spodoptera ; Swine* ; Vaccines

6

Cite

Share

Immunogenicity and efficacy of a plasmid DNA rabies vaccine incorporating Myd88 as a genetic adjuvant.

Padinjaremattathil Thankappan ULLAS ; Anita DESAI ; Shampur Narayan MADHUSUDANA

Clinical and Experimental Vaccine Research.2014;3(2):202-211. doi:10.7774/cevr.2014.3.2.202

PURPOSE: Myeloid differentiation factor 88 (Myd88), a ubiquitous Toll-like receptor adaptor molecule, has been reported to play important roles in B cell responses to infections and vaccination. The present study evaluated the effects of genetic adjuvanting with Myd88 on the immune responses to a plasmid DNA rabies vaccine. MATERIALS AND METHODS: Plasmids encoding rabies glycoprotein alone (pIRES-Rgp) or a fragment of Myd88 gene in addition (pIRES-Rgp-Myd) were constructed and administered intramuscularly or intrademally in Swiss albino mice (on days 0, 7, and 21). Rabies virus neutralizing antibody (RVNA) titres were estimated in the mice sera on days 14 and 28 by rapid fluorescent focus inhibition test. The protective efficacy of the constructs was evaluated by an intracerebral challenge with challenge virus standard virus on day 35. RESULTS: Co-expression of Myd88 increased RVNA responses to pIRES-Rgp by 3- and 2-folds, following intramuscular and intradermal immunization, respectively. pIRES-Rgp protected 80% of the mice following intramuscular and intradermal immunizations, while pIRES-Rgp-Myd afforded 100% protection following similar administrations. CONCLUSION: Genetic adjuvanting with Myd88 enhanced the RVNA responses and protective efficacy of a plasmid DNA rabies vaccine. This strategy might be useful for rabies vaccination of canines in the field, and needs further evaluation.
Animals ; Antibodies, Neutralizing ; DNA* ; Glycoproteins ; Immunization ; Mice ; Myeloid Differentiation Factor 88 ; Plasmids* ; Rabies ; Rabies Vaccines* ; Rabies virus ; Toll-Like Receptors ; Vaccination ; Vaccines, DNA

7

Cite

Share

Assessment of mOMV adjuvant efficacy in the pathogenic H1N1 influenza virus vaccine.

Byeong Jae LEE ; Hyeok Il KWON ; Eun Ha KIM ; Su Jin PARK ; Sang Ho LEE ; Young Ki CHOI ; Sang Hyun KIM

Clinical and Experimental Vaccine Research.2014;3(2):194-201. doi:10.7774/cevr.2014.3.2.194

PURPOSE: Since the pandemic (H1N1) 2009 virus has been a seasonal flu which still poses great human health concerns worldwide, vaccination would be considered as the most effective strategy to control the influenza virus spreading. Here, we assessed adjuvant efficacy of modified outer membrane vesicle (mOMV) towards the pandemic H1N1 split antigen. MATERIALS AND METHODS: For this study, mice were vaccinated twice with various amount of antigen (0.05, 0.1, and 0.5 microg/dose hemagglutinin [HA]) that were mixed with mOMV, aluminum hydroxide (alum), and MF59, as well as the combined adjuvant comprising the mOMV plus alum. RESULTS: We found that all the adjuvanted vaccines of A/California/04/09 (CA04, H1N1) containing HA antigen more than 0.1 microg/dose protected effectively from lethal challenge (maCA04, H1N1) virus, compared to the antigen only group. Furthermore, vaccinated mice received as low as 0.05 microg/dose of the split vaccine containing the combined adjuvant (10 microg of mOMV plus alum) showed a full protection against lethal challenge with H1N1 virus. Taken together, these results suggest that mOMV can exert not only the self-adjuvanticity but also a synergy effect for the vaccine efficacy when combined with alum. CONCLUSION: Our results indicate that mOMV could be a promising vaccine adjuvant by itself and it could be used as a vaccine platform for development of various vaccine formulations to prepare future influenza pandemic.
Aluminum Hydroxide ; Animals ; Hemagglutinins ; Humans ; Influenza A virus ; Influenza A Virus, H1N1 Subtype ; Influenza, Human ; Membranes ; Mice ; Orthomyxoviridae* ; Pandemics ; Seasons ; Vaccination ; Vaccines

8

Cite

Share

Influenza virus vaccine for neglected hosts: horses and dogs.

Woonsung NA ; Minjoo YEOM ; Huijoon YUK ; Hyoungjoon MOON ; Bokyu KANG ; Daesub SONG

Clinical and Experimental Vaccine Research.2016;5(2):117-124. doi:10.7774/cevr.2016.5.2.117

This study provides information regarding vaccine research and the epidemiology of influenza virus in neglected hosts (horses and dogs). Equine influenza virus (EIV) causes a highly contagious disease in horses and other equids, and outbreaks have occurred worldwide. EIV has resulted in costly damage to the horse industry and has the ability of cross the host species barrier from horses to dogs. Canine influenza is a virus of equine or avian origin and infects companion animals that live in close contact with humans; this results in possible exposure to the seasonal epizootic influenza virus. There have been case reports of genetic reassortment between human and canine influenza viruses, which results in high virulence and the ability of transmission to ferrets. This emphasizes the need for vaccine research on neglected hosts to update knowledge on current strains and to advance technology for controlling influenza outbreaks for public health.
Animals ; Disease Outbreaks ; Dogs* ; Epidemiology ; Ferrets ; Horses* ; Humans ; Influenza A virus ; Influenza Vaccines ; Influenza, Human* ; Orthomyxoviridae* ; Pets ; Public Health ; Seasons ; Virulence

9

Cite

Share

Development of vaccines to Mycobacterium avium subsp. paratuberculosis infection.

Hong Tae PARK ; Han Sang YOO

Clinical and Experimental Vaccine Research.2016;5(2):108-116. doi:10.7774/cevr.2016.5.2.108

Johne's disease or paratuberculosis is a chronic debilitating disease in ruminants caused by Mycobacterium avium subsp. paratuberculosis (MAP). The disease causes significant economic losses in livestock industries worldwide. There are no effective control measures to eradicate the disease because there are no appropriate diagnostic methods to detect subclinically infected animals. Therefore, it is very difficult to control the disease using only test and cull strategies. Vaccination against paratuberculosis has been considered as an alternative strategy to control the disease when combined with management interventions. Understanding host-pathogen interactions is extremely important to development of vaccines. It has long been known that Th1-mediated cellular immune responses are play a crucial role in protection against MAP infection. However, recent studies suggested that innate immune responses are more closely related to protective effects than adaptive immunity. Based on this understanding, several attempts have been made to develop vaccines against paratuberculosis. A variety of ideas for designing novel vaccines have emerged, and the tests of the efficacy of these vaccines are conducted constantly. However, no effective vaccines are commercially available. In this study, studies of the development of vaccines for MAP were reviewed and summarized.
Adaptive Immunity ; Animals ; Host-Pathogen Interactions ; Immunity, Cellular ; Immunity, Innate ; Livestock ; Mycobacterium avium subsp. paratuberculosis* ; Mycobacterium avium* ; Mycobacterium* ; Paratuberculosis ; Ruminants ; Vaccination ; Vaccines*

10

Cite

Share

Accelerating the development of a group A Streptococcus vaccine: an urgent public health need.

Jean Louis EXCLER ; Jerome H KIM

Clinical and Experimental Vaccine Research.2016;5(2):101-107. doi:10.7774/cevr.2016.5.2.101

Group A Streptococcus (GAS) infections cause substantial worldwide morbidity and mortality, mostly associated with suppurative complications such as pharyngitis, impetigo, and non-suppurative immune syndromes such as acute rheumatic fever, rheumatic heart disease, and acute post-streptococcal glomerulonephritis. Deaths occur mostly in children, adolescents, and young adults in particular pregnant women in low- and middle-income countries. GAS strains are highly variable, and a GAS vaccine would need to overcome the issue of multiple strains. Several approaches have been used multivalent vaccines using N-terminal polypeptides of different M protein; conserved M protein vaccines with antigens from the conserved C-repeat portion of the M protein; incorporation selected T- and B-cell epitopes from the C-repeat region in a synthetic polypeptide or shorter single minimal B-cell epitopes from this same region; and non-M protein approaches utilizing highly conserved motives of streptococcal C5a peptidase, GAS carbohydrate and streptococcal fibronectin-binding proteins. A GAS vaccine represents urgent need for this neglected disease and should therefore deserve the greatest attention of international organizations, donors, and vaccine manufacturers.
Adolescent ; Child ; Epitopes, B-Lymphocyte ; Female ; Glomerulonephritis ; Humans ; Impetigo ; Mortality ; Neglected Diseases ; Peptides ; Pharyngitis ; Pregnant Women ; Public Health* ; Rheumatic Fever ; Rheumatic Heart Disease ; Streptococcus* ; Tissue Donors ; Vaccines ; Young Adult

DISPLAY OPTIONS

Cite

Share

Cite

Share

Cite

Share

Cite

Share

Cite

Share

Cite

Share

Cite

Share

Cite

Share

Cite

Share

Cite

Share